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1. Introduction 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer 
worldwide. The majority of cases present with locally advanced, non-metastatic HNSCC for 
which the survival rates are approximately 50% at 5 years. Primary surgery followed by 
chemoradiotherapy (CRT) or definitive platinum-containing CRT are the standard 
therapeutic approaches utilized in locally advanced HNSCC. In the updated MACH-NC 
meta-analysis, CRT resulted in an absolute 8% improvement in overall survival (OS) at 5 
years (Pignon et al., 2007; Pignon et al., 2009). However, despite incremental therapeutic 
advances, the problems of locoregional recurrences, distant metastases, organ preservation, 
and toxicity amelioration remain a significant challenge. 
Several molecular pathways are deregulated and activated in HNSCC making it attractive 
area for the evaluation of the recently available and in-development molecular targeted 
therapies. Among the pathways implicated in the development of HNSCC are the 
epidermal growth factor receptor (EGFR) pathway and the vascular endothelial growth 
factor (VEGF) receptor pathway. In this chapter we will review the current data with 
completed and ongoing trials with molecular targeted therapies in the management of 
locally advanced HNSCC. 
2. Epidermal growth factor receptor inhibitors 
EGFR is a member of the human epidermal growth factor receptor family of receptor 
tyrosine kinases that is overexpressed in most HNSCC cases. Signal activation with natural 
ligand fixation to EGFR leads to receptor homodimerization or heterodimerization with 
other HER receptors occurs which in turn leads to the activation of downstream signaling 
molecular pathways. These pathways, including the Ras/Raf/Mek/Erk and the 
phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) pathways, are involved in 
tumor proliferation, apoptosis, angiogenesis, and cell migration/invasion. Increased EGFR 
expression as well as a high EGFR gene copy number are associated with worsened survival 
outcomes (Grandis et al., 1998; Ang et al., 2002). EGFR inhibition is a promising strategy in 
HNSCC since it results in inhibition of tumor cell proliferation, potentiation of apoptotsis 
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and antiangiogenic effects (Ciardiello, 2005; Hirata et al., 2002). Currently available anti-
EGFR therapeutic agents can be classified into monoclonal antibodies (mAbs) and tyrosine 
kinase inhibitors (TKIs). 
2.1 Monoclonal antibodies against EGFR 
Monoclonal antibodies directed against EGFR inhibit activation of distinct EGFR signaling 
pathways and inhibit tumor growth through cell cycle arrest, pro-apoptotic effect, and 
inhibition of angiogenesis, invasion and metastasis, and possibly immune mechanisms 
(Baselga et al., 2000; Mendelsohn & Baselga, 2003). Moreover, anti-EGFR antibodies can 
augment the antitumor activity of RT and chemotherapy (Huan & Harari, 2000; Milas et al., 
2004; Baselga et al., 1993; Fan et al., 1993). 
 
Characteristic Cetuximab Nimotuzumab Zalutumab Panitumumab 
Ig subclass IgG1 IgG1 IgG1 IgG2 
Type Chimeric Humanized Fully human Fully human 
Status Phase III Phase III Phase III Phase III 
Table 1. Current EGFR antibodies in evaluation in head and neck cancers 
2.1.1 Cetuximab 
Cetuximab is a chimeric human-murine monoclonal antibody that binds competitively to 
the EGFR with a higher affinity than its endogenous ligands. It has been studied extensively 
in HNSCC in several phase II and III studies and was approved by the FDA, in combination 
with RT for the treatment of patients with locally advanced head and neck cancer.  
2.1.1.1 Cetuximab and radiotherapy alone 
Bonner et al have published updated 5-year survival results of their pivotal phase III study 
which compared RT alone (n = 213 patients) with cetuximab plus RT (n = 211 patient) in 
patients locally advanced HNSCC of the oropharynx, hypopharynx, or larynx (Bonner et al., 
2010). Patients were stratified by their Karnofsky performance score (60-80 versus 90-100), 
Tumor stage (T1-3 versus T4), N stage (N0 versus N1-3), and radiotherapy fractionation. The 
primary endpoint of the trial was duration of locoregional control and the secondary 
endpoints were quality of life and overall survival. 
The updated median OS for patients treated with cetuximab and radiotherapy was 49 
months versus 29.3 months in the RT alone group (p= 0.018). The 5-year OS rates for the 
cetuximab-RT and RT-alone groups were 45.6 months and 36.4 mmonths, respectively. 
Patients treated with cetuximab had a 26% reduction in the risk of death (hazard ratio [HR], 
0.74%; 95% confidence interval [CI], 0.57-0.97) and a 9% absolute benefit in OS rate at 5 
years. Though locoregional disease control was positively impacted with the addition of 
cetuximab (HR, 0.68; p = 0.005) there was no such impact upon distant disease control. In 
subgroup analysis, median OS values for patient receiving cetuximab-RT versus RT alone 
were statistically significantly different for primary tumor T1-T3 stage (69.5 months versus 
41.4 months), N1-3 neck nodes (53 versus 26.9 months), stage II-III patients (69.5 months 
versus 46.9 months), and stage IV patients (43.2 months versus 24.2 months). 
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A forest plot analysis was done to assess whether certain patient groups benefitted with the 
addition of cetuximab to RT. In this analysis, factors which were associated with a potential 
increased benefit included presence of oropharyngeal tumors, concomitant boost RT, early T 
stage (T1-T3), high Karnofsky performance score (90%-100%), male sex, and age < 65 years. 
These results are provocative but given that the trial was not powered for this subgroup 
analysis, they should be interpreted with caution. 
Patients who received cetuximab commonly developed an acneiform rash (83.7%); the 
severity of the rash was grade 3-4 in 16.8% patients. Infusion-related reactions were also 
seen in 15.4% patients; in 3.9% patients these were of grade 3/4 severity. However, in-field 
toxicities, such as mucositis, dermatitis, and dysphagia did not significantly increase with 
the addition of cetuximab to RT. Quality-of-life parameters were not adversely affected by 
the addition of cetuximab. This study allowed different RT fractionation regimens which 
may have impacted results and survival outcomes.  
Based on the results of this study, the combination of cetuximab with RT is considered an 
alternative to platinum-based CRT for the treatment of locally advanced HNSCC and has 
been included in the National Comprehensive Cancer Network (NCCN) guidelines as an 
option for the treatment of locoregionally advanced HNSCC since 2007.  
2.1.1.2 Cetuximab and chemoradiotherapy 
The favorable results with the use of cetuximab plus RT have led to the adoption of this 
regimen in locally advanced HNSCC. A natural progression has been the evaluation of 
integration of cetuximab into existing chemoradiotherapy, typically involving platinum-
based regimens. Several phase II studies from various groups have been conducted. Larger 
randomized trials have been launched and more recently the preliminary results of a 
randomized study evaluating the combination of cisplatin, cetuximab, and RT in this setting 
have been presented. 
Multiple phase II studies have investigated the integration of cetuximab with standard 
platinum-based CRT regimens. A pilot study from the Memorial Sloan Kettering group 
evaluated 22 patients treated with accelerated fractionation by concomitant boost RT and 
cisplatin (100 mg/m2 on weeks 1 and 4) plus weekly cetuximab (Pfister et al., 2006). In this 
study, acute toxicities were typical of cisplatin-RT and cetuximab was related to grade 3/4 
acneiform rash (10%) and infusion reactions (5%). However, the trial was closed 
prematurely due to significant adverse events including 2 deaths (one due pneumonia, one 
unknown cause), one myocardial infacrction, one bacteremia, and one atrial fibrillation. The 
3-year PFS and OS rates were 76% and 56%, respectively.  
In other studies, the combination of cisplatin and cetuximab concurrently with standard RT 
has not shown such an adverse event profile. This combination was evaluated in a phase II 
study by the Eastern Cooperative Oncology Group (ECOG) in patients with unresectable 
locally advanced HNSCC (E3303) (Langer et al., 2008). Cisplatin (75 mg/m2 every 3 weeks 
for 3 doses) was combined with weekly cetuximab followed by maintenance cetuximab for 6 
months in responding patients with tolerable toxicity. Of 61 patients actually treated on 
study, the overall response rate was 48% with stable disease in 31% patients. The major 
grade 3/4 toxicities included neutropenia (26%), rash (28%), dermatitis (15%), mucositis 
(55%) and one death (neutropenic fever). The CR rate was 36.7% and maintenance 
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cetuximab could be given in 74.6% patients. The 2-year PFS was 44% and the median PFS 
was 17.4 months. The 2-year OS was 66% with a median OS of 34.2 months. The patterns of 
relapse included distant (54.2%), regional (16.6%), both distant and regional (8.3%), local 
and regional (8.3%) and local only in 1 patient (4.2%).  
In a randomized phase II study from the Radiation Therapy Oncology Group, 238 high-risk 
patients with resected HNSCC were randomized to receive weekly cetuximab with either 
weekly cisplatin 30 mg/m2 or weekly docetaxel 15 mg/m2 with 60 Gy RT over a 6-week 
period (RTOG 0234) (Kies et al., 2009). Patients were considered high-risk based on positive 
margins, > 2 involved lymph nodes or extracapsular nodal spread. Data were available on 
203 patients, 97 in the cisplatin arm and 106 in the docetaxel arm. Major grade 3/4 toxicities 
in the cispaltin and docetaxel arms included neutropenia (28% and 14%), mucositis (37% 
and 33%) and dermatitis (33% each) in the cisplatin and docetaxel groups, respectively. The 
2-year OS in the cisplatin and docetaxel arms were 69% and 79%, respectively. Likewise, the 
2-year DFS in the cisplatin and docetaxel arms were 57% and 66%, respectively. The 2-years 
distant metastasis rates with docetaxel and cisplatin were 26% and 13%, respectively and 
this in turn was most likely responsible for the improvement in DFS in the docetaxel arm.  
In an Italian study, Merlano et al have evaluated the combination of 3 cycles of every 3-
weeks cisplatin (20 mg/m2/day X 5 days) and 5-fluorouracil (200 mgm2/day X 5 days) 
with weekly cetuximab and rapidly alternated to 3 split courses of RT (70 Gy) (Merlano et 
al., 2011). In 45 patients treated, the overall RR was 91% with a CR rate of 71%. Major grade 
3/4 toxicities included stomatitis (65%), neutropenia (40%), thrombocytopenia (15%), and 
grade 3 radiodermatitis (74%) with 3 patients dying during therapy. The median PFS and 
OS were reported at 21+ months and 32.6+ months, respectively. 
The combination of amifostine, cetuximab, weekly cisplatin (30 mg/m2) along with 
conformal/hypofractionated RT (2.7 Gy/fraction, total 21 fractions in 4 weeks) was 
evaluated in a Greek study by Koukourakis et al. (Koukourakis et al., 2010). In this study, 43 
patients were treated with the dosing of amifostine individualized according to tolerance. 
High dose and standard dose amifostine were tolerated by 41.8% and 34.9% patients, 
respectively and high dose amifostine was linked to reduced RT delays. Grade 3/4 
mucositis occurred in 16.2% patients, fungal infections occurred in 41.8% patients, and 
cetuximab interruptions due to acneiform rash were necessary in 23.3% of patients. The 
complete response rate was 68.5% and the 2-year local control and survival rates were 72.3% 
and 91% respectively.  
Suntharalingam et al from the University of Maryland group evaluated cetuximab with 
weekly carboplatin (AUC 2), paclitaxel (40 mg/m2) and 70.2 Gy RT in 43 patients with 
unresectable disease (Suntharalingham et al., 2011). The planned cetuximab and 
chemotherapy cycles were completed in 70% and 56% patients, respectively. Major 
toxicities included grade 3 mucositis (79%), dysphagia (21%), radiodermatitis (16%), rash 
(9%), and grade 3/4 neutropenia (21%). The CR rate was 84% at end of therapy and the 
estimated 3-year locoregional control rate was 72%. Local and distant recurrences were 
seen in 6 and 10 patients, respectively. The 3-year actuarial OS and DFS rates were 59% 
and 58%, respectively. 
Birnbaum et al from the Brown University Oncology Group have evaluated a short 4-week 
cetuximab “induction” period followed by cetuximab with weekly carboplatin (AUC 1), 
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paclitaxel (40 mg/m2) and concurrent RT to 66-72 Gy in 32 patients (Birnbaum et al., 2010). 
Patients were stratified by operable or inoperable disease. Patients with potentially 
resectable disease underwent interim tumor biopsy after 5 weeks CRT; positive biopsy 
patients underwent salvage surgery and the others completed CRT. Grade 3/4 
radiodermatitis occurred in 53% patients which was increased compared to the prior 
experience with the chemotherapy regimen alone by these investigators. With a minimum 
follow-up of 3 years, the updated analysis shows the PFS and OS to be 53% and 59%, 
respectively. The rates of local, distant and combined recurrences were 22%, 15%, and 7%, 
respectively. The investigators detected no improvement in local control or distant 
metastasis free survival compared to their prior results with chemotherapy-RT alone. 
Kao et al have evaluated the addition of cetuximab to the well-described non-platinum FHX 
regimen consisting of 5-fluorouracil, hydroxyurea, and hyperfractionated intensity 
modulated radiotherapy in 33 patients with locally advanced HNSCC (Kao et al., 2011). 
Prior organ-conserving surgery was allowed. RT was administered in 1.5 Gy fractions twice 
daily during weeks 1, 3, 5, and 7 to a median dose of 72 Gy. Grade 3 toxicity consisted of 
mucositis (33%), radiodermatitis (15%),neutropenia (12%) and thrombocytopenia (3%). The 
2-year rates of locoregional control, DFS, and OS were 83%, 69%, and 86%, respectively. 
There were no grade 4 events and 64% patients completed treatment without requiring a 
feeding tube. 
A large randomized phase III study was completed by the RTOG that compared accelerated 
fractionation RT by concomitant boost and cisplatin with or without cetuximab in patients 
with previously untreated, locally advanced HNSCC (Ang et al., 2011). A total of 940 
patients with stage III-IV oropharynx, hypopharynx, and larynx cancers with Zubrod 
performance scores 0-1 were randomized to one either the experimental arm of cisplatin 
(100 mg/m2 every 3 weeks x 2 doses), weekly cetuximab and RT (42 fractions, total dose 70-
72 Gy) over 6 weeks or the same regimen without cetuximab. Of 895 evaluable patients, 497 
patients were randomized to the experimental arm and 448 patients to the standard arm. 
The primary tumor sites were oropharynx (70%) and larynx (23%). Among the experimental 
and standard arms, the distribution of stage IV disease (85% vs. 87%), T3-4 stage (60% vs. 
62%) and node-positive disease (88% vs. 90%) were fairly well balanced.  
The primary endpoint of this study was PFS and the secondary endpoints were OS, toxicity 
and early mortality. Interim analyses were planned at 108, 217, and 325 events and a 
planned subgroup analysis for interaction of p16 status with treatment outcomes was 
conducted. With a target accrual of 940 patients, the study was powered at 84% to detect a 
HR of 0.75. The trial was ended early after the third interim analysis showed that it was 
unlikely to meet its primary endpoint. 
The cetuximab-containing arm had higher rates of grade 3/4 mucositis (43% versus 33%, 
p=0.003), in-field skin toxicity (25% versus 15%, p<0.001), out-of-field skin reactions (19% 
versus 1%, p < 0.001) but grade 3/4 dysphagia rates were similar (62% versus 66%, p=0.27). 
The rates of 30-day mortality were similar (2% versus 1.8%) as were the total grade 3-5 
adverse event rates (92% versus 90%).  
With a median follow-up of 2.4 years for surviving patients, there were no significant 
differences in 2-year PFS rates (63.4% versus 64.3%) or OS (82.6% versus 79.7%). The risk of 
distant metastases was numerically reduced in the experimental arm by 26% (HR 0.74,  
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p = 0.7) while the risk of locoregional progression was numerically higher in the cetuximab 
arm (HR 1.21, p=0.92). In a planned subgroup analysis, 321 of 628 patients with oropharynx 
cancer were evaluated for HPV p16 status. The p16 positivity rate was 73% (235 patients) 
and both PFS and OS did not differ according to the PFS status. 
 
Treatment 
Regimen 
Patients (n) Responses Toxicity Reference 
CETUXIMAB AND CRT ALONE 
CRT: cisplatin (2 
cycles), cetuximab 
and RT over 6 
weeks 
22 RR: 94% 
3-year PFS and 
OS: 56% and 
76% 
Major grade 3/4 
cetuximab-
related toxicities 
were rash (10%) 
and 
hypersensitivity 
(5%); study 
closed due to 
significant 
adverse events. 
Pfister et al, 2006 
CRT: cisplatin, 
cetuximab and RT 
Maintenance:  
cetuximab x 6 
months (E3303) 
61(unresectable) RR: 48%2-year 
PFS and OS: 
44% and 66% 
Major grade 3/4 
toxicities were 
neutropenia 
(26%), rash (28%), 
dermatitis (15%), 
mucositis (55%); 
one patient death 
Langer et al, 2008 
CRT:cetuximab, 
RT, plus weekly 
cisplatin or 
weekly docetaxel 
(RTOG 0234) 
 
203 
(postoperative) 
2-year DFS: 57% 
(cisplatin) and 
66% (docetaxel) 
Major grade 3/4 
toxicities were: 
radiodermatitis 
(39% each) and 
mucositis (37% 
vs. 33%) 
Kies et al, 2009  
CRT: cisplatin & 
5-FU x 3 cycles, 
weekly cetuximab 
and split-course 
RT 
45(unresectable) RR: 91 
CR: 71%% 
PFS: 21+ mths 
OS: 32.6+ mths 
Major grade 3/4 
toxicities were 
neutropenia 
(40%), stomatitis 
(65%)and 
radiodermatitis 
(73%); 3 patient 
deaths 
Merlano et al, 
2011 
CRT:amifostine, 
cetuximab, 
weekly cisplatin, 
and RT 
43 CR: 68.5% 
2-year OS: 91% 
Major grade 3/4 
toxicities were 
mucositis (16%), 
fungal infections 
(42%); cervical 
strictures in 
(33%) 
Koukourakis et 
al, 2010 
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Treatment 
Regimen 
Patients (n) Responses Toxicity Reference 
CETUXIMAB AND CRT ALONE 
CRT: weekly 
carboplatin, 
paclitaxel, RT and 
cetuximab  
43 (unresectable) CR: 84% 
3-year OS and 
DFS: 59% and 
58% 
Major toxicities 
were grade 3 
mucositis (79%), 
dysphagia (21%), 
radiodermatitis 
(16%), rash (9%), 
and grade 3/4 
neutropenia 
(21%) 
Suntharalingam 
et al, 2011 
CRT: cetuximab, 
5-FU, 
hydroxyurea, 
hypefractionated 
RT 
32 3-year OS and 
PFS: 54% and 
53% 
Major grade 3/4 
toxicities were 
mucositis (69%); 
radiodermatitis 
(53%), acneiform 
rash (9%) 
Birnbaum et al, 
2010 
CRT: weekly 
carboplatin, 
paclitaxel, RT and 
cetuximab 
33 2-year DFS and 
OS: 69% and 
86% 
Major grade 3 
toxicities were 
mucositis (33%), 
radiodermatitis 
(15%), and 
neutropenia 
(12%) 
Kao et al, 2011 
CRT: chemoradiotherapy; RT: radiotherapy; RR: response rate; CR; complete response; PFS: progression 
free survival; DFS: disease free survival; OS: overall survival 
Table 2. Selected Trials Incorporating Cetuximab with Chemotherapy and Radiotherapy 
2.1.1.3 Induction chemotherapy prior to cetuximab and radiotherapy 
A French randomized phase II study (TREMPLIN) evaluated IC with 3 cycles of the TPF 
regimen followed by either every 3-week 100 mg/m2 cisplatin with RT (arm A) or 
cetuximab with RT (arm B) in patients with laryngeal or hypopharyngeal cancer. (Lefebvre 
et al., 2011) Patients with a less than 50% response to IC underwent salvage surgery while 
responding patients were randomized to either of the 2 combined modality regimens. The 
primary end point was laryngeal preservation. Of 153 enrolled patients, 116 patients could 
be randomized, 60 to arm A and 56 to arm B. There was no difference between cisplatin-RT 
and cetuximab-RT in terms of 3-month or 18-month larynx function preservation. At 32 
months mean follow-up, there were more local failures in the cetuximab-RT arm (12 versus 
5); however, 7 patients could be effectively salvaged in the cetuximab arm leading to 
equivalent ultimate local failure rates. The rates for OS for arm A and arm B were 85% and 
85%; respectively. The cetuximab-RT arm was better tolerated leading to improved 
treatment delivery (71% versus 43%).  
A Swedish phase II has evaluated has similarly evaluated 2 cycles of IC with TPF 
chemotherapy followed by cetuximab-RT in patients with locally advanced unresectable 
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HNSCC (Mercke et al., 2011). Among 90 patients enrolled upon this study, the 1-year DFS 
rate was 86%. This approach was associated with mostly acute toxicities but there were few 
long-term toxicities. 
2.1.1.4 Cetuximab as part of Induction Chemotherapy (IC) regimens 
In recurrent or metastatic HNSCC, cetuximab can augment the efficacy of chemotherapy. In 
a randomized study, 442 patients with recurrent or metastatic HNSCC were randomly 
assigned to therapy with platinum- containing doublet chemotherapy with or without 
cetuximab (Vermorken et al., 2008). The addition of cetuximab improved response rates by 
16% and the median overall survival by 2.7 months, with a reduction in the risk of death of 
20% (HR, 0.80); (p = 0.04). Consequently, cetuximab has been evaluated as part of induction 
therapy in a number of CRT trials in HNSCC.  
The University of Pittsburgh group has published results evaluating IC consisting of 
docetaxel, cisplatin, and cetuximab (TPE) followed by RT, cisplatin, and cetuximab (XPE) 
which was followed by maintenance cetuximab for 6 months in 39 patients (Argiris et al., 
2010). Among 37 evaluable patients, the overall objective response was 86% after IC and 
100% after CRT. Using positron emission tomography scanning, the primary site complete 
response rates after IC and CRT were 59% and 77%, respectively. With a median follow-up 
of 36 months, the 3-year PFS and OS were 70% and 74%; respectively. Relapses were seen in 
locoregional sites (8 patients), distant (3 patients) or both (1 patient). Significant grade 3/4 
hematologic toxicity was common during TPE, including neutropenia in 77% and febrile 
neutropenia in10%. Human paplilloma virus (HPV) positivity was not associated with 
treatment efficacy. This regimen was deemed was highly effective with promising long-term 
survival and was recommended for further testing in larger trials. 
In a multicenter phase II study, the Eastern Cooperative Oncology Group (ECOG) 
evaluated a short 6-week IC regimen with weekly carboplatin, paclitaxel, and cetuximab 
(E2303) in operable locally advanced HNSCC (Wanebo et al., 2010). Induction was 
followed by CRT consisting of weekly doses of same agents. Primary site biopsies were 
done after completion of IC if if there was a clinical response. After the first 5 weeks of 
CRT (50 Gy), repeat primary site biopsy was done in all patients. At this point, biopsy-
negative patients continued to receive CRT to a final dose of 68-72 Gy, whereas patients 
with biopsy-positive results underwent salvage surgery. Maintenance cetuximab was then 
administered to all patients for 6 months. Seventy patients underwent IC, 68 patients 
underwent CRT; 63 patients are available for analysis. Of 41 patients undergoing biopsy 
after IC, the pathologic complete response rate was 59%. After 5 weeks CRT, 60 patients 
underwent re-biopsies among whom the pathologic complete response rates were 95%. Of 
the 63 patients eligible for analysis, the pathologic complete response rate was 91%. Local, 
regional, and distant recurrence rates were 11%, 8% and 8%, respectively. At 2 years, 
primary site disease control was 83%, PFS was 66% and OS was 82%. HPV status did not 
correlate with responses or survival (Psyrri et al., 2011). These preliminary findings 
suggest that this approach produces high primary site pathologic complete response rates 
and survival rates. This approach of selective organ preservation has been previously 
tested by the authors using a similar regimen without cetuximab but is not standard 
practice (Ready et al., 2011; Wanebo et al., 2010). 
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Treatment 
Regimen 
Patients (n) Responses Toxicity Reference 
IC: docetaxel, 
cisplatin, and 
cetuximab x 3 
cycles CRT:  
cisplatin, 
cetuximab and RT 
Maintenance: 6 
mths cetuximab  
39 (resectable 
patients= 33) 
RR: 86% after IC 
and 100% after 
CRT  
CR: 5% after IC 
and 24% after 
CRT 
3-year PFS and 
OS: 70% and 
74% 
During IC: major grade 
3/4 toxicities were 
neutropenia 77%, febrile 
neutropenia 10% During 
CRT: major grade 3/4 
toxicities were mucositis 
54%, dermatitis 27%, 
neutropenia 36%, 
thrombocytopenia 12%, 
febrile neutropenia 6% 
Argiris et 
al, 2010 
IC: paclitaxel, 
carboplatin , and 
cetuximab x 6 
weeks 
CRT: paclitaxel, 
carboplatin, 
cetuximab and RT  
Maintenance: 6 
mths cetuximab 
(E2303) 
70 (operable 
patients) 
Pathologic CR: 
63% after IC 
and 97% after 
CRT 
2-year DFS and 
OS: 62% and 
82% 
During CRT: major 
grade 3/4 toxicities 
were mucositis (32%) , 
neutropenia (31%), rash 
(9%), radiation 
dermatitis (13%); one 
patient death 
Wanebo 
et al, 2010 
IC: paclitaxel, 
carboplatin , and 
cetuximab x 6 
weeks 
Follow-up therapy: 
surgery, RT or CRT  
47 
(resectable) 
RR: 96% after IC 
CR: 19% after IC 
3-year DFS and 
OS: 87% and 
91% 
During IC: grade 3 rash 
(45%), grade 3/4 
neutropenia (21%), no 
deaths during IC 
Kies et al, 
2010 
IC: docetaxel, 
cisplatin, 5-FU and 
cetuximab x 4 
cycles 
CRT: cetuximab, 
RT 
50 
(unresectable 
patients) 
RR: 78% after IC 
CR: 24% after IC 
2-year DFS and 
OS: 42% and 
60% 
During IC: febrile 
neutropenia (26%); 2 
deaths 
During CRT: grade 3/4 
toxicities mucositis 
(56%), dermatitis (10%) 
Mesia et 
al, 2010  
IC: carboplatin, 
paclitaxel, 
cetuximab x 2 
cycles 
CRT: either RT 
plus CetuxFHX 
(cetuximab, 5-FU, 
hydroxyurea) OR 
CetuxPX 
(cetuximab, 
cisplatin) 
110 RR: 91.8% after 
IC  
2-year OS: 
89.5% with 
CetuxFHX and 
91.4% with 
CetuxPX 
During IC: major grade 
3/4 toxicities were rash 
(16%) and neutropenia 
(36%) 
During CRT: major 
grade 3/4 toxicities in 
CetuxFHX were 
mucositis (91%), 
dermatitis (82%) and in 
Cetux PX were 
mucositis (94%) and 
dermatitis (50%) 
Seiwert et 
al, 2011 
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Treatment 
Regimen 
Patients (n) Responses Toxicity Reference 
IC: docetaxel, 
cisplatin, 5-FU 
(TPF) 
CRT: cisplatin plus 
RT versus 
cetuximab plus RT 
(TREMPLIN) 
153 
(resectable; 
116 went on 
to CRT arms) 
OS: 85% in both 
arms at 32 mths  
More treatment delivery 
in cetuximab arm (71%) 
vs cisplatin arm (43%) 
Lefebvre 
et al, 2011 
IC: docetaxel, 
cisplatin, 5-FU 
(TPF) CRT: 
cetuximab, RT 
90 
(unresectable) 
RR: 58% after IC  
DFS: 86% at 1-
year 
Grade 3 radiodermatitis 
4%, cetuximab delays 
20%, mostly acute 
toxicities 
Mercke et 
al, 2011 
IC: induction chemotherapy; CRT: chemoradiotherapy; RT: radiotherapy; RR: response rate; CR; 
complete response; PFS: progression free survival; DFS: disease free survival; OS: overall survival 
Table 3. Selected Trials of Induction Chemotherapy Regimens incorporating Cetuximab. 
The MD Anderson Cancer Center group has published results of their phase II study of 
dose-dense weekly IC regimen consisting of paclitaxel, carboplatin, and cetuximab for 6 
weeks along with G-CSF. IC was followed by locoregional therapy with either surgery, RT 
alone, or cisplatin-RT. This regimen was highly active with a CR and OR rate of 19% and 
96%, respectively. Six patients had relapses; locoregional in 4 patients, distant in 1 patient 
and both in 1 patient. The 3-year PFS and OS rates were 87% and 91%, respectively; HPV 
status was found to correlate with both PFS and OS (Kies et al., 2010). 
The combination of docetaxel, cisplatin, 5-Fluorouracil plus cetuximab (TPF-C) as IC has 
been investigated in a Spanish multicenter phase II study (Mesia et al., 2009). Fifty 
patients with unresectable HNSCC were treated with 4 cycles of TPF-C chemotherapy 
along with G-CSF and antibiotic prophylaxis, followed by accelerated boost RT with 
concurrent cetuximab alone. The ORR after IC and end of CRT were 78% and 72%, 
respectively (intent-to-treat population) with only 86% patients starting CRT. 
Locoregional disease control at 1-year was 44%. With a median follow-up of 19 months, 
actuarial disease free survival and overall survival at 2 years were 42% and 60%, 
respectively.  
Another approach as practiced by the University of Chicago group, has been to evaluate IC 
containing cetuximab, carboplatin, paclitaxel for 2 cycles followed by randomization to one 
of 2 CRT approaches: concurrent cetuximab, 5-fluorouracil, hydroxyurea and 
hyperfractionated RT (CetuxFHX) or cetuximab, cisplatin, and accelerated RT with 
concomitant boost (CetuxPX) (Seiwert et al., 2011). In the preliminary report, 110 patients 
had a overall response rate of 91.8% with IC. After end of all treatment, the 2-year OS in the 
CetuxFHX and CetuxPX arms was 89.5% and 91.4%, respectively. The 2-year PFS for 
CetuxFHX and CetuxPX was 82.3% and 89.7%, respectively. Even though the trial was 
marked by high rates of severe rash, dermatitis, mucositis, and neutropenia 95% of patients 
were able to complete all therapy. Survival outcomes between the two CRT arms were not 
significantly different. 
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2.1.2 Panitumumab 
Panitumumab is a fully human IgG2 antibody that binds with high affinity to the EGFR and 
is approved in the setting of recurrent colorectal cancer. Panitumumab has been evaluated 
in preclinical studies for HNSCC (Lopez-Albaitero & Ferris, 2007; Kruser et al., 2008) which 
showed a favorable interaction between panitumumab and RT.  
Wirth et al have conducted a phase I study of panitumumab in combination with CRT for 
which the preliminary results have been presented (Wirth et al., 2008). In this study, 19 
patients with locally advanced HNSCC received IMRT (70 Gy) with concurrent weekly 
dosing of carboplatin (AUC 1.5) plus panitumumab (2.5 mg/kg) plus paclitaxel (2 dose 
levels, 15 and 30 mg/m2) over a 7-week period. At the higher paclitaxel dose level 1 patient 
developed febrile neutropenia which was considered a dose limiting event. Major toxicities 
included grade 3 dysphagia (95%), grade 3 radiodermatitis (42%), and grade 3/4 mucositis 
(89%). Among evaluable patients, the primary site CR rate was 87%.  
Panitumumab is being evaluated in the postoperative setting in resected locally advanced 
HNSCC with high-risk features (extracapsular nodal spread, > 2 nodes involved, perineural 
or angiolymphatic invasion, or < 1mm margins) (Ferris et al., 2010). The treatment consisted 
of RT (60-66 Gy) over 6-7 weeks concurrent with weekly panitumumab (2.5 mg/kg) and 
cisplatin (30 mg/m2). The planned accrual is 47 patients and final results of this study are 
awaited. Other trials with panitumumab in combination with CRT are currently ongoing. 
2.1.3 Nimotuzumab 
Nimotuzumab is a humanized IgG1 monoclonal antibody against EGFR developed in Cuba. 
This was originally a mouse IgG2a antibody (R3) which was humanized and the resulting 
antibody (h-R3) inhibits EGFR by binding to domain III of the extracellular domain. 
Nimotuzumab partially blocks the EGF binding site as well as stabilizes a receptor-protein 
configuration that is unfavorable for dimer formation. In pre-clinical evaluation, 
nimotuzumab reduced tumor proliferation, increased apoptosis, and had a lower binding 
affinity to EGFR than cetuximab.  
2.1.3.1 Nimotuzumab and radiotherapy alone 
Several early studies have been conducted with nimotuzumab as a single agent in combination 
with RT alone in locally advanced HNSCC. It is well tolerated as a single agent at weekly 
doses up to 400 mg and is associated with a very low incidence of rash (Boku et al., 2009).  
In a phase I/II trial conducted in Cuba, Crombet et al enrolled 24 patients with unresectable 
HNSCC who received 6 weekly infusions of nimotuzumab administered concurrently with 
RT to a total dose of 60-66 Gy (Crombet et al., 2004). Initially, nimotuzumab doses were 
escalated from 50 mg to 400 mg weekly and the last 10 patients were treated at 200 mg or 
400 mg weekly only. This combination was well tolerated without the development of skin 
toxicities while common adverse events were infusion reactions, grade 3 radiodermatitis 
(12.5%), grade 3 mucositis (20.8%), and grade 3 dysphagia (12.5%). The overall RR was 
87.5% among 16 evaluable patients responded and the CR rate was 56%. The OS appeared 
to correlate with the administered dose level, with the 3-year survival rate ranging from 
16.7% for the 2 lower doses to 66.7% for the 2 higher doses. Based on serum levels, the 
nimotuzumab dose of 200 mg/week was selected for further clinical testing.  
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In a follow-up study by the same group, Rodriguez et al performed a randomized phase II 
study in which they evaluated the combination of 6 weekly doses of nimotuzumab and RT 
(60-66 Gy) to patients treated with placebo plus RT in locally advanced unresectable 
HNSCC (Rodriguez et al., 2010). A total of 106 patients were enrolled; 54 on the 
nimotuzumab arm and 51 in the standard arm. Grade 1/2 events attributable to 
nimotuzumab included asthenia (14.6%), fever (9.8%), headache (9.8%), chills (7.8%), and 
anorexia (7.8%). Consistent with other reports, no acneiform skin rash was observed, 
differentiating nimotuzumab from other anti-EGFR antibodies. There was no significant 
exacerbation of adverse events with the addition of nimotuzumab to RT. Among 75 patients 
evaluable for response, the CR rates for the nimotuzumab and placebo groups were 59.5% 
and 34.2%, respectively. In the intent to treat analysis, the median OS differed significantly 
between the nimotuzumab and placebo arms at 12.5 months and 9.5 months, respectively. In 
a subset analysis, patients with at least weak EGFR-expression had an improvement in 
median OS compared to EGFR-negative patients (16.5 months versus 7.2 months, p=0.0038)  
In a small Spanish study, Rojo et al evaluated nimotuzumab (200 mg and 400 mg doses) plus 
RT in 10 patients with advanced HNSCC felt to be unsuitable for CRT (Rojo et al., 2008). The 
overall response rate was 80% and median OS was 7.2 months. Nimotuzumab was well 
tolerated and no skin rash was observed again. Pharmacodynamic studies were conducted 
in this study which showed that nimotuzumab inhibited EGFR phopshorylation; molecular 
downstream effects included decrease of p-ERK and upregulation of p-AKT in tumor but 
not in the skin. There were no associations between doses or responses and 
pharmacodynamic effects in this study. 
2.1.3.2 Nimotuzumab and chemoradiotherapy 
In an open-label, phase IIb randomized study from India, Babu et al evaluated 
nimotuzumab in patients with locally advanced, inoperative HNSCC (Babu et al., 2010). Of 
113 screened patients, 92 were randomized to receive a) RT alone, b) RT plus nimotuzumab, 
c) RT plus cisplatin, and d) RT plus cisplatin plus nimotuzumab. The nimotuzumab dose 
was 200 mg/week x 6 weeks, the cisplatin dose was 50 mg/week, and RT was given to a 
total dose of 60-6 Gy all over 6 weeks. Of 76 evaluable patients, the locoregional response 
rates were as follows: RT (37%), RT plus nimotuzumab (76%), RT plus cisplatin (70%), and 
RT plus cisplatin plus nimotuzumab (100%). Similarly, after 48 months follow-up the 
median OS rates were as follows: RT (12.7 months), RT plus nimotuzumab (14.3 months), 
RT plus cisplatin (21.9 months), and RT plus cisplatin plus nimotuzumab (not reached). The 
addition of nimotuzumab to CRT resulted in this small population resulted in significant 
reduction in the risk of death (HR 0.35, p=0.01).  
Preliminary results of another study from India were reported by Gupta et al in which 17 
patients with locally advanced HNSCC were treated with weekly doses of nimotuzumab 
200 mg plus cisplatin 40 mg/m2 concurrent with RT (66 Gy in 33 fractions) (Gupta et al., 
2010). All patients completed planned nimotuzumab treatments and were evaluated for the 
primary endpoint of responses and safety. No grade 3/4 adverse events were reported. The 
overall RR was 76% (CR 59%) while 2 patients progressed after therapy (one patient each in 
the 5th and 6th month). Additional clinical trials, including a randomized phase III evaluation 
in the postoperative treatment setting is planned. 
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2.2 EGFR tyrosine kinase inhibitors 
EGFR tyrosine kinase inhibitors (EGFR-TKIs) are a class of oral drugs which bind 
intracellularly to EGFR and competitively inhibit the receptor activity resulting in inhibition 
of downstream signaling pathways (Steeghs et al., 2007). In HNSCC, the EGFR-TKIs which 
have been evaluated are erlotinib, gefitinib, and lapatinib. 
2.2.1 Erlotinib 
Erlotinib is an approved drug in advanced non-small cell lung cancer as monotherapy and 
in advanced pancreatic cancer in combination with gemcitabine. In recurrent or metastatic 
HNSCC, erlotinib has been evaluated as monotherapy and in combination with other 
chemotherapeutic agents. 
In a phase I trial Savvides et al combined erlotinib with docetaxel and RT in locally 
advanced HNSCC (Savvides et al., 2006). The regimen consisted of weekly docetaxel (15 to 
20 mg/m2) plus daily erlotinib (50 to 150 mg) with concurrent RT (70 Gy) followed by 
maintenance erlotinib for up to 2 years. One patient developed dose-limiting toxicities at 
each of the first 3 levels but no dose-limiting toxicity was observed at the 4th dose level. The 
CR rate was 83% (15 of 18 evaluable patients) and full dose erlotinib and docetaxel 20 
mg/m2 weekly were the recommended for phase II evaluation. 
Herchenhorn et al conducted a phase I/II study in Brazil which evaluated the combination 
of erlotinib (50 to 150 mg), cisplatin (100 mg/m2 every 3 weeks x 3 doses), and RT (70.2 Gy) 
in 37 patients with locally advanced HNSCC (Herchenhorn et al., 2007). The phase II dosing 
of erlotinib at 150 mg dose was evaluated in 31 patients. The CR rate in these patients was 
74%. Major grade 3/4 toxicities were radiodermatitis (51%), nausea (48%), mucositis (29%), 
dysphagia (35%), and vomiting (39%) were the most common adverse events (Herchenhorn 
et al., 2007). With a median follow-up of 37 months, the 3-year PFS and OS rates were 61% 
and 72%, respectively. 
In a Spanish phase I study, de la Vega et al evaluated combination of erlotinib, weekly 
cisplatin, and RT (up to 63 Gy) in resected patients with locally advanced HNSCC (Arias de la 
Vega et al., 2011). Thirteen patients were treated and the recommended phase II evaluation 
dose was full dose erlotinib (150 mg) with weekly cisplatin (30 mg/m2) for 6 weeks. Further 
studies with erlotinib in patients with locally advanced HNSCCHN are ongoing. 
2.2.2 Gefitinib  
Gefitinib is an oral EGFR-TKI with modest single-agent activity in recurrent or metastatic 
HNSCC (Cohen et al., 2003; Cohen et al., 2005; Kirby et al., 2006). However, 2 phase III 
randomized trials did not show survival benefit of single-agent gefitinib over standard 
methotrexate (Stewart et al., 2009) or of docetaxel plus gefitinib versus docetaxel plus 
placebo in patients with recurrent or metastatic HNSCC (Argiris et al., 2009). Multiple 
studies of the combination of gefitinib with RT or CRT in locally advanced HNSCC have 
been conducted. 
Rodriguez et al conducted a phase II trial of multiagent CRT including daily gefitinib (250 
mg) with 2 cycles of infusional 96-hours of cisplatin and 5-fluorouracil, and concurrent 
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hyperfractionated RT (72-74 Gy) followed by maintenance gefitinib for 2 years (Rodriguez et 
al., 2009). Acute toxicities, including transient renal dysfunction and hospital admissions 
were significantly increased with the addition of gefitinib compared to historical controls. 
The 3-year estimates of freedom from recurrence and OS were 72% and 68%, respectively. 
Less than half the patients were projected to complete maintenance gefitinib. The 
investigators concluded that this regimen increased toxicity without improving efficacy. 
The combination of weekly cisplatin (40 mg/m2) and gefitinib (250 mg) plus concomitant 
boost accelerated radiation (72 Gy) was evaluated by Rueda et al in 46 patients with 
unresectable locally advanced HNSCC (Reuda et al., 2007). Grade 3/4 toxicity included 
mucositis (47%), radiodermatitis (14%), rash (5%), diarrhea (2%), and grade 3 neutropenia 
(5%). Response evaluation at 3 months post therapy completion showed a RR of 63% and 
CR rate of 52%. With a median follow-up of 23 months, the 2-year PFS and OS were 47% 
and 56%, respectively. 
A large, double blind, randomized phase II study was reported by Gregoire et al from 
Belgium (Gregoire et al., 2011). In this study, 226 patients with locally advanced HNSCC 
were randomized to gefitinib (250 mg or 500 mg) with cisplatin and RT followed by 
maintenance gefitinib or placebo. The primary objective was 2-year local disease control 
rate. The addition of gefitinib did not improve 2-year local control rates when given 
concurrently with CRT (32.7% versus 33.6%) or as maintenance (28.8% versus 37.4%).  
Treatment 
Regimen 
Patients (n) Responses Toxicity Reference 
Erlotinib and CRT 
CRT: weekly 
docetaxel, 
erlotinib and RT 
Maintenance: 
erlotinib x 2 
years 
23 CR: 83% Mostly acute 
toxicities; one 
patient death 
Savvides et al, 
2006 
CRT: cisplatin x 
3 cycles, daily 
erlotinib and RT 
37(unresectable) CR: 74% 
3-year PFS 
and OS: 61% 
and 72% 
Major grade 3/4 
toxicities were 
nausea (48%), 
vomiting (39%), 
radiodermatitis 
(52%), and 
mucositis (29%) 
Herchenhorn 
et al, 2010 
Gefitinib and CRT 
CRT: 2 cycles 
cisplatin and 5-
FU, daily 
gefitinib and RT 
Maintenance: 
gefitinib x 2 
years 
60 3-year FFR 
and OS : 72% 
and 67% 
Transient renal 
dysfunction 
(28%), re-
hospitalization 
(83%), 5 patient 
deaths, increased 
diarrhea and 
rash with 
gefitinib 
Rodriguez et 
al, 2009 
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Treatment 
Regimen 
Patients (n) Responses Toxicity Reference 
CRT: weekly 
cisplatin, 
gefitinib, and RT 
46 
(unresectable) 
RR: 63% 
CR: 52% 
2-year PFS 
and OS: 47% 
and 56% 
Major grade 3/4 
toxicties were: 
mucositis (47%), 
rash (5%), 
radiodermatitis 
(14%). 
Rueda et al, 
2007 
CRT: cisplatin, 
gefitinib (250mg 
vs. 500 mg) or 
placebo, and RT 
Maintenance: 
gefitinib x 1 year 
226 
(randomized 
phase II) 
2-year LDCR: 
33% each for 
gefitinib vs. 
no gefitinib 
Increase in 
serious adverse 
events in gefitnib 
arms 
Gregoire et al, 
2011 
IC: carboplatin, 
paclitaxel x 2 
cycles 
CRT: RT, 5-FU, 
hydroxyurea, 
and gefitinib 
Maintenance: 
gefitinib x 2 
years 
69 CR: 90% after 
CRT 
4-year PFS 
and OS: 72% 
and 74% 
Major grade 3/4 
toxicties during 
CRT were: 
neutropenia 
(16%), mucositis 
(85%), 
radiodermatitis 
(33%), infection 
(17%) 
Cohen et al, 
2010 
 
IC: docetaxel, 5-
FU, carboplatin, 
and gefitinib x 2 
cycles 
CRT: docetaxel, 
gefitinib and RT 
Maintenance: 
gefitinib x 2 
years 
62 RR: 80% 
CR: 36% 
3- year PFS 
and OS: 41% 
and 54% 
Major grade 3/4 
toxicties were: 
radiodermatitis 
(9%), mucositis 
(57%), 
hospitalizations 
(42%); one 
patient death 
Hainsworth et 
al, 2009 
IC: induction chemotherapy; CRT: chemoradiotherapy; RT: radiotherapy; RR: response rate; CR; 
complete response; PFS: progression free survival; DFS: disease free survival; OS: overall survival 
Table 4. Selected Trials incorporating EGFR-TKI’s in Chemoradiotherapy Regimens 
Gefitinib was well tolerated during both phases but no efficacy improvement was noted. 
Cohen et al have reported the University of Chicago experience with the addition of 
gefitinib to IC and subsequent CRT in a phase II trial (Cohen et al., 2010). Sixty-nine patients 
with locally advanced HNSCC were treated with 2 cycles of carboplatin and paclitaxel 
followed by fluorouracil, hydroxyurea, gefitinib, and twice daily RT followed by 
maintenance gefitinib for 2 years. Major grade 3/4 toxicity during CRT included mucositis 
(85%), radiodermatitis (33%), neutropenia (16%), and infection (17%). The CR rate was 90% 
after completion of CRT. After a median follow-up of 3.5 years, the 4-year PFS and OS s 
were 72% and 74%, respectively.  
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Finally, Hainsworth et al from the Sarah Cannon group treated 62 patients with locally 
advanced HNSCC with an IC regimen of 2 cycles of docetaxel (60 mg/m2) and carboplatin 
(AUC 5) every 3 weeks plus 6 weeks of daily infusional 5-FU (200 mg/m2) and gefitinib (250 
mg) (Hainsworth et al., 2009). CRT consisted of RT (68.4 Gy) with weekly docetaxel (20 
mg/m2) and daily gefitinib 250 mg/d followed by maintenance gefitinib for up to 2 years. 
IC resulted in major grade 3 mucositis (27%) and diarrhea (16%) as well as grade 3/4 
neutropenia (30%). During CRT, the major grade 3/4 toxicities were mucositis (59%) and 
radiodermatitis (9%). The RR after IC and CRT was 46% and 80%, respectively. With a 
median follow-up of 33 months, the 3-year PFS and OS rates were 41% and 54%, 
respectively, which were not superior to survival results reported with CRT alone by the 
same group.  
2.2.3 Lapatinib 
Lapatinib is a dual-inhibitor which targets EGFR and HER-2 and may inhibit their 
dimerization as a result. In preclinical models, lapatinib has synergistic activity with 
chemotherapy and RT (Montemurro et al., 2007). Harrington et al have reported results of a 
phase I trial of the combination of lapatinib (500 mg, 1000 mg, 1500 mg), cisplatin (100 mg/m2 
every 3 weeks x 3 cycles), and RT (66-70 Gy) in 31 patients (Harrington et al., 2009). No DLT’s 
were observed in this evaluation and the recommended lapatinib dose of for phase II 
evaluation was determined as 1500 mg daily. The overall RR was 81% while radiodermatitis, 
mucositis, lymphopenia, and neutropenia were the most common side effects. 
Harringtpon et al have also presented preliminary results of their phase II randomized 
evaluation of lapatinib or placebo, cisplatin, and RT as per the recommended schedule 
above followed by maintenance lapatinib or placebo (Harrington et al., 2010). In 67 patients 
randomized to lapatinib or placebo, the grade 3/4 toxicities were balanced with grade 3 rash 
and diarrhea being more common in the lapatinib arm. The CR rates in the lapatinib and 
standard arms were 53% and 36%, respectively. CRT dose intensities were not adversely 
impacted by lapatinib. Early data showed hazard ratios for PFS and OS by independent 
review of 0.71 and 0.70, respectively. 
2.3 Predictors of outcome after treatment with EGFR inhibitors 
The level of EGFR expression as detected by immunohistochemistry (IHC) has been 
evaluated as a potential biomarker of cetuximab efficacy in HNSCC. In patients with 
metastatic HNSCC, EGFR expression as determined using the DAKO assay with staining 
intensity graded on an ordinal scale 0-3 and staining density assessed according to the 
percentage of cells stained (Kies et al., 2007). High expression was defined as staining 
intensity 3 + on 80% of cells. EGFR expression was not predictive of response to cetuximab 
nor was there any association with survival. 
The University of Pittsburgh group has reported results of evaluation of baseline serum 
biomarkers in their study evaluating cetuximab in locally advanced HNSCC (Ferris et al., 
2009). A panel consisting of 31 cytokines were measured before and after 3 cycles of 
induction cetuximab-containing chemotherapy. Low baseline VEGF and IL-6 levels were 
potentially associated with complete response among patients evaluated by PET imaging 
post-therapy. 
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Fountzilas et al evaluated genetic biomarkers in patients undergoing cetuximab containing 
radiation in locally advanced HNSCC (Fountzilas et al., 2009). In this report, tumor EGFR, 
MET, ERCC1, and p-53 protein and/or gene expression were not associated with treatment 
response. However, a high level of matrix metalloproteinase MMP9 mRNA expression was 
found to be significantly associated with objective response.  
Tumors of patients treated with cisplatin-chemotherapy with or without cetuximab on the 
phase III EXTREME registration study were evaluated for EGFR gene copy number FISH 
(Licitra et al., 2009). Tumors were classified as FISH positive or FISH negative using the 
Colorado scoring system. Patients with FISH positive tumors were evenly distributed across 
both arms. The FISH scores had no influence on the response rate in the cetuximab-
containing arm and no effect on survival on either; thus EGFR gene copy number was not 
predictive of cetuximab efficacy in this setting. In patients treated with gefitnib, cisplatin 
and radiotherapy in locally advanced HNSCC, EGFR protein expression, FISH and 
mutation status did not predict for response or survival (Tan et al., 2011). 
The most common adverse event associated with anti-EGFR agents that occurs in more than 
two-thirds of patients is skin rash which usually occurs in the first 3 weeks of treatment. It is 
likely related to EGFR expression in the skin and the severity of rash is associated with 
efficacy. Several studies in HNSCC have shown a direct correlation between the 
development of rash and better patient outcome after EGFR inhibitor therapy (Soulieres et 
al., 2004; Cohen et al., 2003; Baselga et al., 2005; Burtness et al., 2005; Herbst et al., 2005). In 
the Bonner study, patients with a grade 2 or greater rash had a significantly lower risk of 
death (Bonner et al., 2010). Patients with a prominent rash had significantly longer overall 
survival than those patients who had a mild rash (68.8 months vs. 25.6 months; HR 0.49; 
p=0.002). It is possible that occurrence of acneiform rash is a biomarker of an immunological 
response that is conducive for optimal outcome. It thus seems that currently occurrence of a 
high-grade rash may be the only biomarker predictive of favorable outcome with cetuximab 
containing therapy. 
3. Vascular endothelial growth factor pathway inhibitors 
VEGF was associated with an increased risk of death in HNSCC in a recent meta-analysis of 
12 studies (Kyzas et al., 2005). In HNSCC, both VEGF and the VEGF receptor are 
upregulated and are important for tumor cell survival in hypoxic conditions (Moriyama et 
al., 1997; Denhart et al., 1997; Inoue et al., 1997; Petruzzelli et al., 1997). Pre-clinical studies 
have demonstrated that blockage of the VEGF pathways by anti-angiogenic drugs increases 
the anti-tumor effects of radiation. As such targeting the VEGF pathway through 
monoclonal antibodies and receptor tyrosine kinase inhibitors is a promising therapeutic 
approach in HNSCC. The currently available data with the use of bevacizumab in locally 
advanced HNSCC is reviewed below. 
3.1 Bevacizumab  
The humanized monoclonal antibody bevacizumab binds VEGF-A and is currently 
approved for clinical use in many advanced solid tumors, including colorectal cancer, non-
small cell lung cancer, renal cell carcinoma, and glioblastomas. Bevacizumab inhibits 
angiogenesis and also facilitates chemotherapy delivery into tumors (Shirai & O’Brien, 2007; 
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Olsson et al., 2006). Antiangiogenic agents, in preclinical studies appear to overcome 
resistance and potentiate the effect of traditional therapies such as radiotherapy and 
chemotherapy (Seiwert & Cohen, 2008).  
3.1.1 Bevacizumab and chemoradiotherapy 
Various combinations of bevacizumab and radiotherapy have been evaluated in phase I/II 
trials in locally advanced HNSCC. Seiwert et al from the University of Chicago group have 
published results of a phase I evaluation of bevacizumab, 5-fluorouracil, hydroxyurea, and 
radiation (BFHX). In this study, 43 patients with recurrent, previously irradiated or poor 
prognosis, treatment-naïve HNSCC were treated with every 2-week regimen of 
bevacizumab (escalating doses from 2.5 to 10 mg/kg), hydroxyurea (500-1000 mg BID), and 
5-FU (600-800 mg/m2 as a continuous infusion for 5 days) in combination with RT (1.8-2 Gy 
once daily) on a week on-week off schedule (Seiwert et al., 2008). The MTD of the 
combination was bevacizumab (10 mg/kg), 5-FU (600 mg/m2) and hydroxyurea (500 mg) 
and this cohort was expanded to 26 patients. The median OS was 10.3 months. Significant 
severe late toxicities were observed including development of fistula (5 patients), ulceration 
or tissue necrosis (4 patients), and thrombosis (3 patients).  
Results of a follow-up phase II randomized study by the same group have been reported by 
Salama et al in which the BFHX regimen was compared to the prior FHX regimen (Salama et 
al., 2011). In this study, 26 patients with intermediate stage III-IV patients (excluding N2-N3 
stage) were enrolled. The study was halted following unexpected locoregional progression 
in 4 patients with T4 tumors randomized to the BFHX regimen. The incidence of mucositis 
and dermatitis was not increased with the addition of bevacizumab to CRT. The pathologic 
CR rate on study was 77%. The 2-year OS was 68% and the DFS for BFHX and FHX were 
59% and 89%, respectively. Two patients died during CRT and one patient died within 30 
days after post-CRT surgery. 
Savvides et al have presented preliminary results of a phase II study evaluating the 
combination of weekly docetaxel (20 mg/m2) and every 2-week bevacizumab (5 mg/kg) with 
daily RT (70.2 Gy) followed by maintenance bevacizumab for up to 1 year (Savvides et al., 
2008). Of 23 enrolled patients, 17 patients remained in CR and 4 patients recurred. No 
unexpected toxicities or severe bleeding episodes were noted while 8 patients required 
hospitalization during CRT. The estimated 1-year PFS and OS were 78% and 89%, respectively. 
Preliminary results of a phase II study from the Sloan Kettering group which investigated 
the addition of bevacizumab (15 mg/kg every 3 weeks x 3 cycles) to cisplatin (50 mg/m2 on 
days 1, 2, 22, 23, 43 and 44) and RT (70 Gy) have been presented by Pfister et al (Pfister et al., 
2009). Plans for maintenance bevacizumab were discontinued after the occurrence of a grade 
4 pulmonary hemorrhage. Major toxicities included grade 3 mucositis (76%) and grade 3/4 
neutropenia (41%). Two patients died within 90 days of last treatment; one had a sudden 
death and another died from aspiration pneumonia. The estimated 1-year PFS and OS were 
83% and 88%, respectively.  
Preliminary results of a RTOG phase II trial of bevacizumab and CRT in patients with 
locally advanced nasopharyngeal carcinoma were reported by Lee et al (Lee et al., 2011). In 
this study, 44 patients were enrolled and received 3 cycles of bevacizumab (15 mg/kg), 
cisplatin (100 mg/m2), and IMR (70 Gy) followed by 3 cycles of adjuvant bevacizumab (15 
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mg/kg), cisplatin (80 mg/m2), and 5-fluorouracil (1000 mg/m2/day x 4 days). The most 
common grade 4 toxicity was hematologic and grade 3/4 mucositis was seen in 77% cases. 
The 2-year PFS and OS were 71.7% and 90.9%, respectively. These survival rates were 
favorable compared to prior RTOG data with regards to OS but not PFS. 
3.1.2 Bevacizumab with induction chemotherapy and CRT 
In a phase II study, Meluch et al evaluated IC with paclitaxel (200 mg/m2), carboplatin 
(AUC 6), and 5-FU (200 mg/m2/day x 3 weeks) plus bevacizumab (15 mg/kg) followed by 
concurrent RT (68.4 Gy) with paclitaxel (50 mg/mw/week), bevacizumab (15 mg/kg), and 
erlotinib (150 mg daily) in locally advanced HNSCC (Meluch et al., 2009). Of 60 enrolled 
patients, preliminary results in the first 48 patients showed that the most common grade 3/4 
adverse events during IC were neutropenia (46%), neutropenic fever (6%), mucositis (14%), 
and diarrhea (14%); during CRT grade 3/4 mucositis occurred in 76% patients. The overall 
RR was 77% after completion of the entire treatment. After a median follow-up of 16 
months, the 18-month PFS and OS were 85% and 87%, respectively. No unexpected 
toxicities were observed with this regimen. 
4. Conclusion 
The evaluation of targeted therapies in the management of locally advanced head and neck 
squamous cancers is evolving. Currently, randomized trials data support the use of the anti-
EGFR monoclonal antibody cetuximab in combination with radiotherapy in this setting. 
Conversely, the currently available data do not support the use of cetuximab in combination 
with chemotherapy and radiotherapy in this setting based on the results of the RTOG 0522 
study. As such, the use of combined targeted and chemotherapy regimens outside of a 
clinical trial is not recommended at present. The challenge in the appropriate use of anti-
EGFR therapies is the determination of appropriate patients prospectively through the use 
of relevant biomarkers. Presently, the development of a high-grade rash is the only potential 
biomarker of benefit in the use of ant-EGFR therapy.  
The clinical trials scenario is replete with ongoing randomized trials evaluating anti-EGFR 
monoclonal antibodies and tyrosine kinase inhibitors in combination with chemotherapy. 
Additional trials are investigating the role of anti-VEGF therapies and mTOR inhibitors are 
in early clinical trials. The results of these trials will shape the future of targeted therapies in 
this setting. 
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